Media & Press

  • Phebra welcomes PBS listing of Naproxen

    Naproxen suspension is approved for reinbursement through the Pharmaceutical Benefits Scheme (PBS)

    November 2012

  • TGA approval of Phebra’s Naproxen oral suspension

    The Australian pharmaceutical company Phebra, announced today that the Therapeutic Goods Administration (TGA) has granted Phebra marketing approval for Naproxen oral suspension, an alternative to the previously available Naprosyn® oral suspension.

    October 2012

  • Phebra achieves milestone during new plant construction

    Works continue to progress on the construction of Phebra pharmaceuticals’ new Sydney manufacturing plant.

    May 2012

  • Phebra signs distribution agreement for Digifab

    Phebra signs distribution agreement for Digifab

    January 2012

  • Phebra Pharmaceuticals Welcomes New Federal Ministers

    Phebra Pharmaceuticals Welcomes New Federal Ministers

    December 2011

  • Tadim receives marketing approval in Australia

    Tadim receives marketing approval in Australia

    February 2011

  • Phebra Injects $16 Million into new manufacturing plant

    Phebra Injects $16 Million into new manufacturing plant

    February 2011

  • New $16 Million Manufacturing Plant

    New $16 Million Manufacturing Plant

    January 2011